Podcasts about vaccine development

When Health and Human Services Secretary Robert F. Kennedy Jr. announced new COVID recommendations this week, it raised questions among clinicians and patients:Will those shots still be available to people who want them — and will insurance cover it?NPR's Ari Shapiro speaks with Dr. Peter Hotez, co-director of the Texas Children's Hospital Center for Vaccine Development, about the CDC's new guidelines for healthy children and pregnant women — and whether they could make it more difficult for these patients to get shots if they want them.For sponsor-free episodes of Consider This, sign up for Consider This+ via Apple Podcasts or at plus.npr.org.Email us at considerthis@npr.org.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

“In Big Pharma, innovation is often stifled because the bureaucracy and mindset completely kills creativity and intuition needed for discovery. That's why they now prefer to allocate their early-phase resources to smaller biotechs,” explains Julien Laizé, sharing candid insights about the delicate balance between innovation and compliance in vaccine manufacturingJulien Laizé serves as Director of External Manufacturing CTM at Valneva, a French-based specialty vaccine company developing and commercialising vaccines for infectious diseases. With previous roles at Novo Nordisk and Eli Lilly, Julien brings unique perspectives on managing external manufacturing across both big pharma and biotech environments, particularly in navigating the tension between innovation and regulatory compliance.Ahead of CDMO Live next week, Julien shares his experiences in fostering innovation while maintaining rigorous quality standards, and explains why the industry's greatest discoveries often come from embracing calculated risks.Listen to the full episode here and join Julien and other ExM leaders at CDMO Live 2025, 7-8 May, Rotterdam.

Send us a textIn this conversation, Dr. Paul Offit and pediatrician Jessica Hochman discuss the importance of vaccinations, the challenges of vaccine hesitancy among parents, and the need for nuanced conversations in public health. They explore the impact of the COVID-19 pandemic on public trust, and the science behind vaccination schedules. The discussion emphasizes the importance of understanding parental concerns while advocating for the safety and efficacy of vaccines. About Paul A. Offit, MD!Paul A. Offit, MD, is Director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children's Hospital of Philadelphia. He is the Maurice R. Hilleman Professor of Vaccinology at the Perelman School of Medicine at the University of Pennsylvania.Dr. Offit is an internationally recognized expert in the fields of virology and immunology, and was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention. He is a member of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee, and a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine and co-editor of the foremost vaccine text, Vaccines.He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal.Dr. Offit has published more than 160 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and he was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health.In 2009, Dr. Offit received the President's Certificate for Outstanding Service from the American Academy of Pediatrics. In 2011, he received the Humanitarian of the Year Award from the BiologicDr Jessica Hochman is a board certified pediatrician, mom to three children, and she is very passionate about the health and well being of children. Most of her educational videos are targeted towards general pediatric topics and presented in an easy to understand manner. For more content from Dr Jessica Hochman:Instagram: @AskDrJessicaYouTube channel: Ask Dr JessicaWebsite: www.askdrjessicamd.com-For a plant-based, USDA Organic certified vitamin supplement, check out : Llama Naturals Vitamin and use discount code: DRJESSICA20-To test your child's microbiome and get recommendations, check out: Tiny Health using code: DRJESSICA Do you have a future topic you'd like Dr Jessica Hochman to discuss? Email Dr Jessica Hochman askdrjessicamd@gmail.com.The information presented in Ask Dr Jessica is for general educational purposes only. She does not diagnose medical conditions or formulate treatment plans for specific individuals. If you have a concern about your child's health, be sure to call your child's health care provider.

The S&P and Dow eked out a gain on Monday but all indexes closed the quarter with significant losses. This as investors await the onset of President Trump's tariffs and the announcement of reciprocal levies. Plus the FDA's vaccine head abruptly resigned over the weekend. What that means for drug development in the U.S. Fast Money Disclaimer

Send us a textIn this episode of "The UMB Pulse" podcast, hosts Charles Schelle, MS, and Dana Rampolla chat with Wilbur Chen, MD, MS '08, the Frank M. Calia, MD Endowed Professor of Medicine at the University of Maryland School of Medicine (UMSOM) and chief of the adult clinical studies section at UMSOM's Center for Vaccine Development and Global Health.Chen highlights the importance of federally funded research and the importance of global health efforts for local stability. In addition, Chen addresses current concerns such as the resurgence of measles in the United States and the avian flu outbreak, emphasizing the need for widespread vaccination and sustained research. The episode provides a comprehensive overview of how the University of Maryland, Baltimore is driving forward public health initiatives that have both local and global implications.00:00 Introduction to UMB's Mission00:42 Meet Dr. Wilbur Chen02:59 Dr. Chen's Journey into Infectious Disease Research09:59 The Importance of Indirect Costs in Research18:16 Current Research and Global Health Impact25:12 Measles Outbreaks in the U.S.35:45 Avian Flu and Its Implications47:55 Global Health Challenges and Future Pandemics58:11 Conclusion and Final ThoughtsListen to The UMB Pulse on Apple, Spotify, Amazon Music, and wherever you like to listen. The UMB Pulse is also now on YouTube.Visit our website at umaryland.edu/pulse or email us at umbpulse@umaryland.edu.

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the company has been awarded a grant from the Medical CBRN Defense Consortium to support the continued development of its next-generation vaccine candidate. MCDC is a consortium comprising industrial, academic, and non-profit organizations that assist the U.S. government in advancing medical solutions to protect against chemical, biological, radiological, and nuclear threats. Dr. Lederman explained that the vaccine candidate is being developed as an improved immunization option for mpox and smallpox, with the potential for delivery via innovative alternative methods designed to enhance patient compliance, ease of administration, and overall tolerability. The MCDC grant will support comprehensive market analyses, target market identification, and commercialization planning for both private and government sectors. The investigational vaccine is a minimally replicating live-virus formulation based on a modified orthopoxvirus. It has demonstrated the ability to provide single-dose immune protection against mpox in preclinical studies while offering improved tolerability compared to traditional live-virus vaccines. Previous studies have also shown its effectiveness in protecting animals from lethal intratracheal exposure to a more virulent strain of the mpox virus. Tonix is currently preparing for Phase 1 clinical trials in both the United States and Kenya. Kenya, which is on the outskirts of an MPOX outbreak in Africa, presents an opportunity to test the vaccine in an area with a growing case burden. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MPOXVaccine #Smallpox #TNX801 #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #ProactiveInvestors

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Joseph Eron, Professor of Medicine at University of North Carolina (UNC) about the topic of his upcoming presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) 2025: HIV Cure Research: State of the Art and Navigating Presentations at CROI 2025. Dr Eron discusses the state of HIV cure research including a detailed discussion of why it has been so difficult to develop a cure for HIV. Dr Saag and Dr Eron discuss the difference between HIV cure and functional cure and provide a detailed overview of cure research efforts looking at blocking and locking HIV in human DNA. Dr Saag and Dr Eron also discuss the potential for “molecular scissors” (CRISPR-Cas9) to cure HIV. Finally, they provide an overview of cure research that will be presented at CROI, highlighting the plenary presentation by Dr Ole Søgaard at CROI on Monday March 10 entitled HIV Cure: A Translational Research Perspective. For more information about the topic of this episode, listen to an earlier episode of Going anti-Viral where Dr Saag discusses Vaccine Development with Dr Richard Koup, see links in the resources below. 0:00 – Introduction1:31 – Defining cure in the context of HIV4:56  – Why is it so hard to cure HIV7:56 – What is functional cure11:47 – Description of the concept of “block and lock” in human DNA14:33 – Discussion of tat inhibitors – blocking of HIV regulatory genes18:02 – Prospect of using “molecular scissors” (CRISPR-Cas9) as a cure23:13 – Highlights in HIV cure research at CROI and closing remarksResources: CROI 2025: https://www.croiconference.org/Going anti-Viral Episode 4 – A Deep Dive into Vaccine Development with Dr Richard Koup: Apple Podcasts: https://podcasts.apple.com/us/podcast/episode-4-a-deep-dive-into-vaccine-development-with/id1713226144?i=1000637677124 YouTube: https://youtu.be/nXeMt3GMj4Q __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of RCA Radio®, host Brandon Miller is joined by Anita Michael, Executive Pharma Compliance Expert & Principal Consultant and Rona LeBlanc-Rivera, Director, Regulatory Affairs both at Regulatory Compliance Associates®.  We explore possible changes in the Pharmaceutical industry in 2025 and provide you with insight on how to prepare yourself for these upcoming initiatives.Listen in as we go over the expected reduction in the FDA's work force, recently executed guidance documents, regulatory timelines, drug labeling transparency, the broadening scope of OTC products, the use of AI in the regulatory review, and how companies can use 3rd party inspections to help prepare themselves. About RCARegulatory Compliance Associates® (RCA) provides worldwide services to the following industries for resolution of compliance and regulatory challenges:PharmaceuticalBiologic & BiotechnologySterile compoundingMedical deviceWe understand the complexities of running a life science business and possess areas of expertise that include every facet of R&D, operations, regulatory affairs, quality, and manufacturing. We are used to working on the front lines and thriving in the scrutiny of FDA-and globally-regulated companies.As your partners, we can negotiate the potential minefield of regulatory, compliance, quality, and private equity due diligence with insight, hindsight, and the clear advantage of our unique expertise and experience.

Today we're talking about Trump's Inauguration Day, and while we're finally heading in the right direction, let's not pretend like everything is perfect. We've got some serious issues to address. Why is Trump still supporting the H-1B visa program that undercuts American jobs? Why didn't he put his hand on the Bible while being sworn in? And why is he backing these creepy AI-driven mRNA vaccines? If we're truly going to fix this country, then we need to face these problems head-on, not ignore them. That's what cowards do.—https://policecoffee.com/

My guest today is Tal Zaks. Tal is a physician-scientist turned biotech executive and investor who served as Moderna's Chief Medical Officer during their COVID-19 vaccine development, giving him an extraordinary perspective on one of modern medicine's pivotal moments. His combination of medical expertise, platform innovation experience, and investing acumen allows us to explore the interconnected challenges of turning scientific breakthroughs into viable medicines while generating venture-scale returns. We dive deep into lessons from Moderna's mRNA platform, examine how emerging technologies might reshape drug development, and the fundamental question of what it means to make people healthier. For investors, entrepreneurs, and anyone interested in the future of medicine, this discussion provides a window into both the immense potential and profound challenges of advancing human health. Please enjoy my conversation with Tal Zaks.  For the full show notes, transcript, and links to mentioned content, check out the episode page here. ----- This episode is brought to you by Ramp. Ramp's mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Ramp is the fastest-growing FinTech company in history, and it's backed by more of my favorite past guests (at least 16 of them!) than probably any other company I'm aware of. Go to Ramp.com/invest to sign up for free and get a $250 welcome bonus. – This episode is brought to you by AlphaSense. AlphaSense has completely transformed the research process with cutting-edge AI technology and a vast collection of top-tier, reliable business content. Imagine completing your research five to ten times faster with search that delivers the most relevant results, helping you make high-conviction decisions with confidence. Invest Like the Best listeners can get a free trial now at Alpha-Sense.com/Invest and experience firsthand how AlphaSense and Tegus help you make smarter decisions faster. –  This episode is brought to you by Ridgeline. Ridgeline has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. I think this platform will become the standard for investment managers, and if you run an investing firm, I highly recommend you find time to speak with them. Head to ridgelineapps.com to learn more about the platform. ----- Invest Like the Best is a property of Colossus, LLC. For more episodes of Invest Like the Best, visit joincolossus.com/episodes.  Follow us on Twitter: @patrick_oshag | @JoinColossus Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Show Notes: (00:00:00) Welcome to Invest Like the Best (00:08:37) State of Medicine Today (00:09:44) Investment and Innovation in Medicine (00:13:14) Challenges in Biotech Investment (00:17:18) Personalized Cancer Vaccines (00:22:58) Investing in Biotech: Process and Considerations (00:28:38) Multidisciplinary Approach in Pharma (00:41:35) COVID-19 Vaccine Development (00:46:27) Funding and Manufacturing Challenges (00:48:01) Unprecedented Vaccine Safety Measures (00:50:38) Public Perception and Trust Issues (00:53:54) Future of mRNA and Nucleic Acid Medicines (00:58:04) Personalized Medicine and Data Collection (01:04:48) AI's Role in Healthcare (01:08:34) Investment Strategies in Therapeutics (01:14:57) The Human Element in Medical Innovation (01:21:58) The Kindest Thing Anyone Has Ever Done for Tal

The body's immune response to syphilis and how the response impacts the development of a vaccine is complex. Dr. Tara Reid from the University of Washington Division of Allergy & Infectious Diseases delves into the various responses and the difficulties of vaccine development with Dr. Meena Ramchandani. View episode transcript at www.std.uw.edu.This podcast is dedicated to an STD [sexually transmitted disease] review for health care professionals who are interested in remaining up-to-date on the diagnosis, management, and prevention of STDs. Editor and host Dr. Meena Ramchandani is an Assistant Professor of Medicine at the University of Washington (UW) and Program Director of the UW Infectious Diseases Fellowship Program. 

In this episode, Jonathan sits down with Philip Smith to discuss groundbreaking advancements in gastroenterology, the impact of IBD research, and how his personal journey with Crohn's disease has influenced his career. From international guidelines to the role of digital platforms in healthcare, Smith offers a compelling insight into the future of gastrointestinal medicine.   Timestamps: (00:00)-Introduction (02:35)-Specialising in luminal gastroenterology (05:30)-IBD patient to practitioner (11:20)-Career highs and lows (17:40)-Smith's impactful IBD research (21:02)-The international approach to gastroenterology (25:39)-Screening colonoscopy (29:49)-Advancements and future priorities for IBD care (37:37)- Leveraging social media to engage with the gastroenterology community (43:30)-Identifying high-impact studies as EiC (49:06)-Three wishes for healthcare

In this episode, Jonathan Sackier welcomes Martin Whyte to delve into the intricate world of metabolic medicine. Together, they discuss groundbreaking research on diabetes, non-alcoholic fatty liver disease, and polycystic ovarian syndrome, as well as how metabolic research is shaping the future of preventative care and treatment. Use the following timestamps to navigate this episode:  (00:00)-Introduction (02:10)-Journey into metabolic medicine (03:23)-Advances in Diabetes science (06:22)-Obesity and economic impact (08:28)-Patient terminology discussion (14:55)-Metabolic and chronic conditions (19:21)-Fatty liver disease (25:36)-Preventative health strategies (29:51)-Future of metabolic research (33:13)-Impact of GLP-1 drugs (37:08)-Fertility and menstrual disorders (41:01)-Thee wishes for healthcare

In this eye-opening episode of Good Morning Liberty, hosts Chuck and Nathaniel Paul Thurston delve into the final report from the House's Select Subcommittee on the Coronavirus Pandemic. They discuss numerous government failures during the COVID-19 crisis, including the origins of the virus, mask mandates, vaccine efficacy, lockdowns, and relief funding fraud. Tune in for a candid conversation on the impact of misinformation, the role of public health officials, and the long-term consequences of government actions. The discussion also covers controversial figures like Anthony Fauci and Andrew Cuomo, shedding light on their decisions and their implications for public trust. Don't miss this comprehensive breakdown of one of the most significant crises in modern history. (03:07) Taylor Lorenz's COVID Safe Book Launch (04:59) Select Subcommittee on Coronavirus Pandemic Report (06:27) COVID-19 Origin and Lab Leak Theory (08:51) Government Failures and Fraud During the Pandemic (10:26) WHO and Social Distancing Critique (11:08) Mask Mandates and Lockdowns (12:14) Impact of Lockdowns on Mental Health and Economy (17:08) Vaccine Development and Mandates (23:14) Natural Immunity and Public Health Misinformation (27:35) Conclusion and Call to Action

In this episode, Dr. Stanton Hom sits down with Justin Leslie, a former Pfizer scientist turned whistleblower. Justin discusses his unique journey from working on mRNA COVID-19 vaccines at Pfizer to becoming a pivotal whistleblower exposing inconsistencies and alleged fraud within the company. He shares his experiences with Project Veritas, the challenges he faced during his undercover investigative work, and the motivations behind his decision to speak out. Justin also dives into the consequences of mRNA technology, its impact on human health, and the broader implications for society. Furthermore, he highlights his current efforts to share his story through various platforms and his commitment to advocating for truth and integrity in the pharmaceutical and healthcare industries.   Timestamps: 00:00 Welcome to the Future Generations Podcast 00:37 Meet Justin Leslie: From Pfizer Scientist to Whistleblower 00:59 Unveiling Pfizer's Secrets: A Whistleblower's Journey 02:44 The Path to Pfizer: A Personal and Professional Background 11:16 Diving Deep into Pfizer's Practices and the mRNA Vaccine Controversy 18:54 Exploring the Ethical Quandaries and Scientific Misconduct at Pfizer 28:57 The Whistleblower's Evidence: Uncovering the Truth About Pfizer's Vaccines 33:42 Reflections on the Journey and the Impact of Whistleblowing 35:58 Unveiling the Dark Side of Vaccine Development 36:48 The Ethical Dilemmas and Accountability in Pharma 38:19 Exploring Alternative Media and Whistleblower Challenges 39:32 The Journey of an Undercover Journalist 45:34 Diving Deep into Terrain Theory and Biofields 50:38 The Impact of COVID on Future Generations and Fertility 52:57 A Whistleblower's Mission and Vision for the Future 01:04:47 Supporting the Cause: How You Can Help   Key Takeaways: - Justin Leslie shares his journey from being a Pfizer scientist to becoming a whistleblower, exposing practices and decisions within Pfizer related to the COVID-19 vaccines. - Justin discusses his initial aspirations and how his path led him to Pfizer, where he worked directly on mRNA COVID vaccines and subsequently observed and reported on questionable practices. - Highlights include his concerns about changes in vaccine buffers without public disclosure, the impact of these changes on children's vaccinations, and discrepancies in vaccine trial data. - Justin elaborates on his undercover work with Project Veritas, decision-making processes within Pfizer, and the challenges he faced in exposing the information he discovered. - He talks about the broader implications of his findings, including safety concerns related to vaccine components and their distribution within the body. - The discussion also covers Leslie's post-whistleblower life, his mission to inform the public and promote integrity within journalism and science, and his hopes for creating paradigms of truth and health. - Justin emphasizes the importance of questioning narratives, seeking truth, and the role of each individual in shaping a free and informed future.   Resources:   Remember to Rate, Review, and Subscribe on iTunes and Follow us on Spotify!   Learn more about Justin Leslie: Websites: https://justintegrity.net/ https://linktr.ee/justinleslie    Instagram:  https://www.instagram.com/justin.leslie3/    X: https://x.com/justintegrity_    Learn more about Dr. Stanton Hom on: Instagram: https://www.instagram.com/drstantonhom  Website: https://futuregenerationssd.com/    Podcast Website: https://thefuturegen.com Twitter: https://twitter.com/drstantonhom  LinkedIn: https://www.linkedin.com/in/stanhomdc    Stay Connected with the Future Generations Podcast: Instagram:  https://www.instagram.com/futuregenpodcast  https://www.instagram.com/thefuturegensd  https://www.instagram.com/drstantonhom    Facebook: https://www.facebook.com/futuregenpodcast/  https://www.facebook.com/thefuturegensd/  If you would like to learn more about the truth behind the pandemic, please check out The End of C0V1D.  Click the link to sign up: https://theendofcovid.com/ref/352/    Get the Heart of Freedom III Replay here: https://hof3replay.thefuturegen.com/hof3recording  Join the Future Generations Community here: https://community.thefuturegen.com  San Diego area residents, take advantage of our special New Patient offer exclusively for podcast listeners here. We can't wait to experience miracles with you!   If you've been dreaming about a soul filling career that involves supporting women to birth in a holistic, empowered way (while actually getting paid top $$ to do so), consider this your formal invitation to Uncovering Birth Doula Training. Dr. Stan's brilliant friend and colleague Eyla Cuenca is a Childbirth Educator, Doula, health freedom advocate & birth trauma alchemist – and on

On this week's episode of The Van Maren Show, Jonathon speaks with Christian Hacking of the Center for Bio-Ethical Reform (CBR) UK about his recent research on the gruesome connection between abortion and vaccine development.LSNTV Apple Store: https://apps.apple.com/us/app/lsntv/id6469105564LSNTV Google Play: https://play.google.com/store/apps/details?id=com.lifesitenews.app****SHOP ALL YOUR FUN AND FAVORITE LIFESITE MERCH! https://shop.lifesitenews.com/+++Connect with John-Henry Westen and all of LifeSiteNews on social media:LifeSite: https://linktr.ee/lifesitenewsJohn-Henry Westen: https://linktr.ee/jhwesten Hosted on Acast. See acast.com/privacy for more information.

Challenges and solutions in monitoring assay performance for vaccine development: an interview with Atul Chaudhari

Dr. Alessio Fasano, who is considered the world's leading expert in celiac disease and gluten-related disorders, returns for his second appearance on STEM-Talk. Although just 2 million Americans have celiac disease, an estimated 20 million Americans suffer from gluten sensitivity. Alessio is a professor and director of the Mucosal Immunology and Biology Research Center at Massachusetts General Hospital. In addition to celiac disease and gluten-related disorders, Alessio's research is also focused on the microbiome, intestinal permeability and autoimmune disorders, which he discussed in his first interview on STEM-Talk, episode 20. Since Alessio's first appearance on STEM-Talk in 2016, he has published two books, “Gluten Freedom” and “Gut Feelings: The Microbiome and Our Health,” which we discuss in today's interview. We also talk to Alessio about an exciting new project that's bringing together an international consortium of researchers and scientists for a long-term study that will follow infants who are genetically at risk of developing celiac. Alessio is a researcher and physician who wears many hats. He is the director of the Center for Celiac Research and Treatment and chief of the Division of Pediatric Gastroenterology and Nutrition at Mass General Hospital. He also is a professor of pediatrics at Harvard Medical School and a professor of nutrition at Harvard's T.H. Chan School of Public Health. Show notes: [00:03:58] Marcas opens the interview welcoming Alessio back to STEM-Talk, mentioning that since his last appearance he has written two books: Gluten Freedom and Gut Feelings: The Microbiome and Our Health. Marcas asks Alessio how he became interested in pediatrics and gastroenterology. [00:05:42] Ken mentions that Alessio moved to the U.S. in the 1990s and spent 20 years in Maryland at the Center for Vaccine Development in Baltimore. Ken goes on to mention that while Alessio was there, he founded The Center for Celiac Research in 1996, and in 2003, Alessio accepted an offer to join Massachusetts General Hospital. Ken asks how that move came about. [00:08:53] Marcas asks about Alessio's early career working on cholera, where he discovered the zonula occuldens toxin, the bacteria that causes cholera. Marcas asks Alessio to talk about this finding and the insights he gleaned from it. [00:16:03] Ken asks about Alessio's discovery of zonulin, which is the molecule that modulates gut permeability in humans. Ken asks Alessio to share how this discovery led him to investigate celiac disease, which is triggered by gluten. [00:20:25] Ken asks Alessio what his thoughts are on why the medical community, historically, has not taken celiac disease seriously. [00:24:08] Marcas mentions that as we age, there is evidence that the gut becomes leakier, which is highly related to chronic inflammation. Marcas asks Alessio whether this happens to the gut over time due to diet and lifestyle rather than the typical aging process. [00:28:45] Ken mentions that there has been an increase in the diagnosis of celiac disease. Ken asks Alessio if that is due to an actual increase in the prevalence of the disease, or is it tied to a growing appreciation that clinicians have now for the disease? [00:29:32] Marcas mentions that Alessio's book, Gluten Freedom, which he co-authored with his colleague Susie Flaherty, was referred to by the Celiac Disease Foundation as “a must have,” and “an excellent reference for those with gluten related disorders.” Marcas asks Alessio about this reception to his book. [00:31:24] Marcas mentions that the only viable treatment for individuals with celiac disease has been a gluten-free diet, with pharmaceutical companies having had little interest until recently in investigating the disease. Now there are more than 20 drug therapies in development for celiac. Marcas asks Alessio about the progress being made to develop pharmacological interventions for celiac.

Pink Sheet editors discuss Medicare spending projections for the Alzheimer's treatment Leqembi (:28), Janet Woodcock's new post-FDA role (12:28), and ongoing preparations for new pneumococcal vaccines that will reach the market soon (17:28). #business #pharma More On These Topics From The Pink Sheet Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer's Drug Costs: https://pink.citeline.com/PS150095/Medicare-Spending-Forecast-For-Leqembi-Reflects-CMS-Angst-About-Alzheimers-Drug-Costs Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm's Length: https://pink.citeline.com/PS150111/Woodcock-Takes-On-Rare-Disease-Challenges-In-Retirement-Keeps-FDA-Industry-At-Arms-Length Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck's V116: https://pink.citeline.com/PS150029/Change-Is-Constant-For-Pneumococcal-Vaccines-US-CDC-Prepares-For-Mercks-V116

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Breakthrough in Cancer ResearchScientists have made a significant breakthrough in cancer research, discovering a new potential treatment that targets specific cancer cells without harming healthy cells. This discovery has the potential to revolutionize cancer treatment and improve outcomes for patients.## Drug Approval for Rare DiseaseThe FDA has approved a new drug for a rare genetic disease that affects only a small percentage of the population. This approval is a major milestone in the treatment of rare diseases and provides hope for patients who previously had limited options for treatment.## Vaccine Development ProgressResearchers have made significant progress in the development of a new vaccine for a highly infectious disease. This vaccine has shown promising results in early clinical trials and could potentially prevent outbreaks and save countless lives in the future.## Collaboration for Drug DiscoveryTwo leading pharmaceutical companies have announced a collaboration to accelerate drug discovery efforts for a range of diseases. By combining their resources and expertise, these companies aim to bring new treatments to market faster and more efficiently.## Regulatory Approval for New TreatmentA new treatment for a common chronic condition has received regulatory approval, paving the way for patients to access this potentially life-changing therapy. This approval is a result of years of research and development, bringing hope to millions of patients around the world.## ConclusionIn conclusion, recent advancements in cancer research, rare disease treatment, vaccine development, drug discovery, and regulatory approval are all contributing to significant progress in the pharmaceutical and biotech industries. These breakthroughs have the potential to improve patient outcomes, save lives, and drive innovation in the healthcare sector. Stay tuned for more updates on the latest developments in Pharma and Biotech."

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Breakthrough in Cancer TreatmentA recent study published in the Journal of Oncology reported a groundbreaking new treatment for certain types of cancer. The treatment, which involves a combination of immunotherapy and targeted therapy, has shown promising results in clinical trials. Patients who received the treatment experienced a significant reduction in tumor size and improved overall survival rates. Researchers are hopeful that this new approach could change the way we treat cancer in the future.## FDA Approval for New DrugThe Food and Drug Administration has approved a new drug for the treatment of a rare genetic disorder. The drug, which is the first of its kind, works by targeting the underlying cause of the disorder rather than just managing symptoms. Clinical trials have shown that patients who took the drug experienced a significant improvement in their condition compared to those who received a placebo. This approval marks a major milestone in the field of rare disease treatment.## Collaboration Between Pharma CompaniesTwo leading pharmaceutical companies have announced a collaboration to develop a new vaccine for a common infectious disease. The companies will combine their expertise and resources to expedite the development process and bring the vaccine to market as quickly as possible. This collaboration highlights the importance of partnerships in advancing medical research and improving public health. Both companies are optimistic about the potential impact of this new vaccine on global health.## Investment in Biotech StartupsVenture capital firms have been increasing their investments in biotech startups, signaling growing confidence in the industry. These startups are focused on developing innovative treatments for a wide range of diseases, from cancer to rare genetic disorders. The influx of funding will help accelerate research and development efforts, bringing new therapies to market faster. This trend bodes well for the future of biotechnology and its potential to revolutionize healthcare.## ConclusionIn conclusion, recent developments in cancer treatment, FDA approvals, pharma collaborations, and biotech investments are shaping the landscape of healthcare innovation. These advancements hold promise for improving patient outcomes and addressing unmet medical needs. As we continue to see progress in these areas, it is clear that the future of healthcare is bright. Stay tuned for more updates on the latest news and breakthroughs in Pharma and Biotech.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Breakthrough in Cancer TreatmentA recent study published in a leading medical journal has shown promising results in a new cancer treatment. Researchers discovered a novel combination of drugs that effectively target specific cancer cells while minimizing damage to healthy cells. This breakthrough could potentially revolutionize the way we approach cancer treatment in the future.## Regulatory Approval for New DrugIn other news, a new drug has received regulatory approval for the treatment of a rare genetic disorder. This drug has been shown to significantly improve symptoms and quality of life for patients suffering from this condition. The approval process was expedited due to the urgent need for effective treatments for this rare disease.## Partnership for Vaccine DevelopmentA major pharmaceutical company has announced a partnership with a leading research institution to develop a new vaccine. This collaboration brings together expertise in vaccine development and cutting-edge research capabilities to address current and future public health challenges. The goal is to accelerate the development and distribution of this much-needed vaccine.## Clinical Trial Results for Alzheimer's TreatmentExciting news in the field of Alzheimer's treatment as the results of a recent clinical trial have shown promising outcomes. The experimental drug has been found to slow down the progression of the disease in patients, offering hope for those affected by this devastating condition. Further research is now underway to validate these findings and potentially bring this treatment to market.## Investment in Biotech Start-UpA biotech start-up has secured a significant investment from a venture capital firm to support its research and development efforts. This funding will enable the company to advance its pipeline of innovative therapies and bring them closer to commercialization. The investment is a testament to the potential of the company's technology and its ability to make a meaningful impact in the biotech industry.## ConclusionThat's all for today's episode of Pharma and Biotech daily. Stay tuned for more updates on the latest developments in the world of pharmaceuticals and biotechnology. Thank you for listening.

It's hotter and wetter than usual in Brazil, and climate conditions are driving an early blast of a killer virus – dengue. The mosquito-borne virus is spreading earlier than ever before and affecting far more parts of the country than usual – and all at once.Dengue's a nasty virus. It causes pain so severe that it's sometimes called breakbone fever. Patients often feel nauseated, develop rashes, and vomit blood. The most severe cases can cause internal bleeding. There's no specific treatment – just fluids and rest, and watching out for signs of shock, which can kill patients within hours.Dengue is unusual because there are four different types, known as serotypes. The first infection is often mild, but people are not immune to the other three serotypes after that first time. The second time someone gets infected, they are more likely to become seriously ill – a phenomenon called antibody-dependent enhancement. Sometimes a vaccine can cause this effect.Brazilian authorities are keeping this in mind as they rush to roll out vaccines to fight this unusually early and widespread epidemic of dengue, says Dr. André Siqueira, principal investigator at the National Institute of Infectious Diseases Evandro Chagas at Fundação Oswaldo Cruz, also known as FioCruz, in Rio de Janeiro.There are nowhere near enough vaccines yet – only six million doses this year, enough to protect just three million people with the two-dose regimen. Brazil's population is more than 200 million.Researchers at Brazil's Butantan Institute are working to develop a new vaccine that should protect people with just one dose and, they hope, will protect against all four serotypes of dengue.Dr. Siqueira is part of the team working on that new vaccine. Listen as he explains to One World, One Health host Maggie Fox why dengue is so bad in Brazil this year and what he and colleagues are doing to control it.

DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.                                                  >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.                                                                                  Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. Hello, and welcome to "DITCH THE LAB COAT," the podcast that strips down medical science and uncovers the core of health issues. I'm your host, Dr. Mark Bonta, and this is episode-3 of our thought-provoking three-part series on Covid-19. Today, we sit with the esteemed Dr. Suman Chakrabarti, our head of infectious diseases at Trillium Health Partners in Mississauga, who will unravel the now, the next, and the nuanced complexities of the pandemic. Despite battling a mild runny nose himself, Dr. Chakrabarti breaks down for us the realities of immune suppression, the risks, the recovery, and the truth behind the social decisions impacting our lives.From the gravity of lockdowns on mental health, education, and the economy to the lessons that could shape future pandemics, we dive deep into the controversies. We'll critique the polarizing divides between vaxxers and anti-vaxxers, maskers and anti-maskers. We'll explore how the pandemic has pressed on the wounds of inequality and delayed essential health care. Dr. Chakrabarti presses on the importance of a balanced approach to illness, the understanding of contagiousness, and the necessity of humility and cooperation. We'll consider the ramifications of our actions and investigate how we can empower rather than instill fear. Strap in as we also discuss the future of vaccination, the promise of mRNA vaccines beyond COVID-19, and the crucial need for personal empowerment over mandatory government intervention.Join us as we cast off the lab coat, and glean valuable insights on adapting, innovating, and thriving amidst this pandemic and the ones to come. Remember, DITCH THE LAB COAT airs every Wednesday morning. Don't miss this engaging conversation with Dr. Suman Chakrabarti, right after this short break.05:37 Balancing safety and practicality in workplace precautions.06:58 Immune suppression varies, impacts differently, precautions necessary.11:17 Balancing work and health during Covid-19.15:01 Stay home if sick, adapt to changes.17:13 Pandemic viruses become less virulent over time.22:02 Friends welcome, risks of gathering acknowledged.26:30 Balancing spending priorities during pandemic response is crucial.28:20 Focus on mental health and healthcare sustainability.32:16 Concerns over pandemic response; need for improvement.35:54 Society should only be shut down when necessary.40:01 Duty and sacrifice emphasized in helping society.43:29 Summary: Discussion about past, present, and future pandemics.45:06 Learning from pandemic to shape future mindset.

Last week, we saw some FDA approvals for a new drug regimens, as well as some expert opinion about cancer vaccines. Additionally research touched upon the potential benefit of concurrent ctDNA and tumor testing, and physical activity for pain reduction in cancer survivors.  FDA Approves Onivyde as First-Line Treatment of Metastatic Pancreatic Cancer On Tuesday, the Food and Drug Administration approved Onivyde plus oxaliplatin, fluorouracil and leucovorin — a regimen referred to as NALIRIFOX — for the frontline treatment of patients with metastatic adenocarcinoma. The approval was based on findings from the NAPOLI 3 trial, which showed that the drug combination improved overall survival (which is the time after treatment patients live before death of any cause) and progression-free survival (time they live before their disease worsens) compared to a combination of gemcitabine plus nab-paclitaxel.  While this approval provides a new, promising treatment for this patient population, Dr. Anthony Shields of the Karmanos Cancer Center in Detroit mentioned that the Onivyde-containing regimen is not a cure.  “In our patients with advanced disease, this is not a curative therapy at this point,” Shields said in an interview with CURE®. “It clearly improves survival. It's still got its share of toxicities, though. … We need better drugs, despite the improvements. If patients get this regimen is the first line, inevitably if they're doing OK we will give gemcitabine/nab-paclitaxel (combination) as the second-line regimen. But we really don't have a third line regimen.” Cancer Vaccine Could Go ‘Above and Beyond Standard of Care' For Patients The oncology community is on the cusp of a sea change regarding cancer vaccines, as one expert told us. “Current vaccines have a dismal record, and minimal evidence of efficacy,” said Dr. Jeffrey S. Weber, deputy director of the NYU Langone Perlmutter Cancer Center and Laura and Isaac Perlmutter Professor of Oncology at NYU Grossman School of Medicine, via email. Weber was among the researchers on recent KEYNOTE-942 study investigating mRNA vaccine mRNA-4157 (V940) and Keytruda versus standalone Keytruda for the treatment of patients with advanced-stage melanoma.With a median follow-up of 23 and 24 months, the recurrence or death rates were 22% and 40% and the 18-month recurrence-free survival rates were 79% and 62%, respectively. The Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to the combination for the post-surgical treatment of patients with high-risk melanoma in 2023 based on the results of KEYNOTE-942. “This mRNA vaccine would be the first approved cancer vaccine with clear cut evidence of efficacy in a well-done phase 3 trial [which was recently initiated],” Weber said of mRNA-4157. Pharmaceutical companies Moderna and Merck have initiated V940-001, a phase 3 study evaluating mRNA-4157 and Keytruda as postsurgical treatment for stage 2B to 4 melanoma, announcing in June of 2023 that global patient recruitment had begun following primary analysis of the findings of KEYNOTE-942. Tumor Testing, ctDNA Finds More Patients Eligible for Personalized Drugs Circulating tumor DNA and tumor tissue-based testing can both help identify cancer characteristics that may point a patient toward a more targeted treatment regimen. Oftentimes, patients undergo only one of these two tests, but recent research showed that undergoing both of these tests may improve patients' chance of identifying targetable mutations.  Now, some patient populations — such as those with non-small cell lung cancer — may already be undergoing both tests in accordance with NCCN guidelines. The findings support that other groups in particular, such as those with breast cancer, may benefit from the dual testing modality.  In an interview with CURE, one of the study authors noted that the two tests can be “highly complementary,” and patients should talk to their health care teams about which test to undergo.  Physical Activity May Help Reduce Pain in Cancer Survivors Increased physical activity may be able to lessen pain in cancer survivors, according to one study.  Specifically, the researchers wrote, “Meeting or exceeding physical activity guidelines was associated with less pain intensity compared to being physically inactive. People who remained active longer term, were previously physically active or became active also reported less pain than those who remained inactive.”  These benefits were also seen in patients who were previously active but then became inactive — highlighting the possibility that the when it comes to pain reduction, the benefits of being active can stretch long-term. But interestingly, the was no association between  physical activity and painkiller use.  For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

Episode 8 - A Historical Overview of The HIV/AIDS Epidemic, Prevention and Intervention Methods, and Future Strategies with Dr Susan BuchbinderIn this episode of the Going anti-Viral podcast, host Dr Michael Saag speaks with Dr Susan Buchbinder, a professor of medicine, epidemiology, and biostatistics at the University of California, San Francisco. They discuss the HIV/AIDS epidemic, tracing its history from its rise in the early 80s to its current status. The conversation covers the efficacy of different preventive and treatment strategies, such as community engagement, behavioral changes, condom use, pre-exposure prophylaxis (PrEP), and the prospects of a future HIV vaccine.00:02 Introduction to the Podcast00:31 Guest Introduction: Dr Susan Buchbinder01:10 History of the HIV Epidemic05:01 The Role of Community in HIV Prevention06:30 Prevention and Interventions07:40 The Importance of HIV Testing10:28 The Revolution of PrEP in HIV Prevention12:42 The Challenges in Ending the HIV Epidemic22:18 The Future of HIV Prevention24:55 Conclusion and Final Thoughts__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

About Deborah Glasser:Deborah Glasser holds an MBA in Marketing and Finance from the University of Chicago Booth School of Business and a B.A. with honors from Tufts University. Deborah is currently the Head of Vaccines in North America at Sanofi. In this role, she spearheads a team committed to pursuing scientific breakthroughs, focusing on the development and enhancement of immunizations. Sanofi, a global pharmaceutical giant, places a strong emphasis on innovation, and Deborah plays a crucial role in driving the vision forward, expanding access to vaccines, and advancing public health initiatives throughout the U.S. and Canada.Drawing on a rich and varied professional background, Deborah brings more than a decade of experience to her current role. Her journey includes an illustrious 13-year tenure at Biogen, where she held diverse positions across its U.S., European, and global organizations. Notably, she played a key role in the successful launch of Tecfidera, an oral multiple sclerosis product that achieved remarkable success, generating $1.3 billion in U.S. sales within its first four full quarters on the market.Things You'll Learn:The vaccine industry faces intense competition.RSV stands as the primary reason for infant hospitalizations.Approximately 70 out of every 100,000 individuals end up hospitalized due to the flu.The flu poses a significant and serious risk, with an average of 36,000 deaths annually, potentially reaching 98,000 in severe seasons. These deaths are preventable.It's crucial to recognize the seriousness of the flu and take preventive measures to avoid unnecessary fatalities.Resources:Connect with and follow Deborah Glasser on LinkedIn.Follow Sanofi on LinkedIn and visit their website.

On today's episode of Danforth Dialogues, Dr. Valerie Montgomery Rice sits down with Dr. Albert Bourla, Chairman and CEO of Pfizer. Join us as we unpack the story behind the decision to invest billions in developing the MRNA vaccine for COVID-19. Dr. Bourla sheds light on the challenges faced, from overcoming skepticism about untested technology to rallying a diverse team in the face of a global crisis.In this thought-provoking conversation, we delve into the intricacies of leadership during a pandemic, the critical role of partnerships with organizations like the NIH, and the profound impact on human lives. Dr. Bourla shares firsthand experiences, revealing the behind-the-scenes efforts that led to the successful development of the vaccine. We also explore the broader implications for the future of healthcare, the importance of combating vaccine misinformation, and the commitment to inclusivity in clinical trials and global vaccine distribution.Stay tuned for a deep dive into the lessons learned, the challenges faced, and the visionary outlook on the intersection of science, leadership, and the collective pursuit of a healthier world. CREDITS Theme Music

Episode 6 - A Conversation With Dr Anthony Fauci on His Career And His Role in the Responses to AIDS and COVID-19. Recorded December 14, 2023 Dr Michael Saag hosts Dr Anthony Fauci on this episode of the Going anti-Viral podcast, discussing Dr Fauci's career journey, his involvement in AIDS research, and his contribution towards managing other viral diseases. The conversation particularly focuses on the initial response to AIDS, the response to the COVID-19 pandemic, the vaccine development process, and the challenges and successes encountered. The podcast also highlights the significant shift in activism around public health crises, contrasting the constructive role of AIDS activists with the destructive anti-science activism faced during COVID-19. 00:02 Introduction and Background00:42 Dr Anthony Fauci's Early Life and Career02:07 Beginning of the AIDS Story02:12 First Encounter with AIDS and Initial Response03:34 The Turning Point in AIDS Research04:16 Building the AIDS Research Team12:04 The Role of Activism in AIDS Research17:06 The Emergence of COVID-1917:55 The Development of the COVID-19 Vaccine25:58 The Challenges of Anti-Science Activism in the COVID-19 Era29:29 The Future of Public Health Communication30:28 Conclusion and Reflections__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

Good morning from Pharma and Biotech daily, the podcast bringing you crucial updates from the Pharma and Biotech world. Today's episode covers several significant developments and deals in the industry.AstraZeneca is on the verge of acquiring vaccine maker Icosavax for up to $1.1 billion. This move underscores AstraZeneca's dedication to vaccine development, particularly as it gains a combination vaccine targeting respiratory viruses. This acquisition is timely, considering the looming expiration of patents for several major medicines, a challenge prompting big pharma to explore new markets.In a notable development, Bristol Myers Squibb (BMS) has acquired rights to develop and commercialize Systimmune's antibody-drug conjugate (ADC) for various cancers, including lung and breast cancer. The deal, potentially worth $8.4 billion, highlights the growing interest in ADCs, a promising class of cancer treatments.Sanofi has terminated its licensing agreement with Maze Therapeutics for a Pompe disease drug following challenges from the US Federal Trade Commission (FTC). The decision to end this deal reflects the heightened regulatory scrutiny within the industry.Reiterating its focus on vaccines, AstraZeneca has also acquired Icosavax in a deal potentially worth $1.1 billion. This acquisition enables AstraZeneca to enter the market for respiratory syncytial virus vaccines, demonstrating its commitment to expanding its vaccine portfolio.In a major industry move, Pfizer's $43 billion acquisition of Seagen has overcome regulatory barriers and is set to conclude. This deal, the largest in recent years, will significantly enhance Pfizer's presence in the ADC market, a trend indicative of the current wave of large-scale acquisitions in pharma.Sino Biological, a biotech firm, has made strides in gene therapy by developing platforms for multi-pass transmembrane protein products. These advancements underscore the industry's progress in drug manufacturing technologies.Employee engagement is gaining importance in the sector, as illustrated by Kyowa Kirin's new program aimed at involving its workforce in shaping the company's future. This approach reflects a broader understanding of the role of employee involvement in fostering innovation and success.Tome Biosciences has launched with a significant funding of $213 million, focusing on genomic medicines, particularly in precision oncology. This move highlights the ongoing advancements in gene therapy and personalized medicine.At the American Society of Hematology (ASH) annual meeting, BMS and 2seventy Bio presented promising survival data for their CAR-T therapy, Abecma, used in treating multiple myeloma. This data points to the potential of CAR-T therapy in treating complex diseases.Novartis' iptacopan showed positive results in a Phase III study for an ultra-rare kidney disease. Coming shortly after FDA approval for another indication, this demonstrates progress in treating rare diseases.Catalent is seeking to expand in the GLP-1 market, used in treating type 2 diabetes, amid a revenue downturn and staff cuts. This move reflects the competitive nature of the diabetes treatment market.The Centers for Medicare and Medicaid Services (CMS) are preparing to announce the 'maximum fair price' for drugs under the Inflation Reduction Act's negotiation program. This impending decision is poised to be a pivotal pharmaceutical trend in 2024, with significant political and economic implications, especially considering the upcoming presidential election.The year 2023 saw four historic FDA approvals, including a vaccine for RSV and a drug for Alzheimer's disease, showcasing ongoing progress in drug development and healthcare.Bryter's insights have been instrumental in pharma's success in marketing rare disease treatments, highlighting the vital role of data analytics and strategic insights in effective marketin

Episode 4 - A Deep Dive into Vaccine Development with Dr Richard Koup, Deputy Director Chief, Immunology Laboratory Vaccine Research Center, NIAID, NIH. This special episode was recorded live from the 2023 Ryan White CLINICAL CONFERENCE in Portland, OR, December 2nd, 2023In this special episode of Going anti-Viral, recorded live from the 2023 Ryan White CLINICAL CONFERENCE in Portland, OR, we explore the challenges and progress in developing vaccines for HIV and COVID-19. Dr Saag discusses with Dr Richard Koup, Deputy Director Chief, Immunology Laboratory Vaccine Research Center, NIAID, NIH, about vaccine development for HIV and its associated challenges and how pre-existing knowledge of similar viruses expedited COVID-19 vaccine development. The conversation also touches upon cellular immunity, broadly neutralizing antibodies, and the potential future of HIV vaccine development.00:08 Introduction and Welcome00:44 Interview with Dr Richard Koup01:05 The History of HIV Vaccine Development02:26 The Challenges of HIV Vaccine Development06:33 The Role of Broadly Neutralizing Antibodies in HIV Vaccine Development14:30 The Potential of Cellular Immunity in HIV Vaccine Development16:08 The Miraculous Development of the COVID-19 Vaccine26:37 The Future of HIV Vaccine Development28:13 Conclusion and Closing Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.

In this episode, hosts Marla Dalton, PE, CAE, and William Schaffner, MD, talk with Peter J. Hotez, MD, PhD, dean of the National School of Tropical Medicine at Baylor College of Medicine. He shares insights from his influential career in vaccine science and diplomacy, from how the field has changed over time, how his experience as the father of an autistic daughter helped shape his career, and what we can all be doing to counter anti-science rhetoric and help build vaccine confidence.Show notesAn internationally recognized physician-scientist, Hotez is a professor at Baylor College of Medicine, co-director of the Texas Children's Center for Vaccine Development, and Texas Children's Hospital Endowed Chair of Tropical Pediatrics. For decades, he has led global efforts to develop new vaccines for neglected diseases around the world affecting hundreds of millions of people. In December of 2021, he led efforts at Texas Children's to develop a low-cost COVID-19vaccine for global health, resulting in emergency use authorization in India. He is also an elected member of the National Academy of Medicine and the American Academy of Arts and Sciences and is the prolific author of more than 650 publications, including the newest book, “The Deadly Rise of Anti-Science: A Scientist's Warning.” He frequently testifies before Congress and appears as a guest for national media outlets, always sporting his distinctive bowtie.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## News 1: New Drug Approved for Cancer TreatmentThe FDA has recently approved a new drug for the treatment of cancer. This drug has shown promising results in clinical trials, with a high success rate in shrinking tumors and improving overall survival rates. It is expected to be available to patients within the next few months.## News 2: Breakthrough in Alzheimer's ResearchScientists have made a significant breakthrough in Alzheimer's research. They have identified a new target for drug development, which could potentially slow down or even halt the progression of the disease. This discovery brings hope to millions of people suffering from Alzheimer's and their families.## News 3: Vaccine Development for Infectious DiseaseResearchers are making progress in the development of a vaccine for a highly infectious disease that has been spreading rapidly. Preliminary results from animal trials have shown promising immune responses, and human trials are set to begin soon. If successful, this vaccine could help prevent further outbreaks and save countless lives.## News 4: Gene Therapy Shows Promise for Genetic DisordersGene therapy has shown great promise in treating genetic disorders. Recent studies have demonstrated significant improvements in patients with various genetic conditions, such as cystic fibrosis and muscular dystrophy. This breakthrough opens up new possibilities for the treatment of previously untreatable diseases.## News 5: Collaboration between Pharmaceutical CompaniesMajor pharmaceutical companies have announced a collaboration to accelerate drug development and improve patient outcomes. By sharing resources and knowledge, these companies aim to bring innovative therapies to market faster and more efficiently. This collaboration has the potential to revolutionize the pharmaceutical industry and benefit patients worldwide.## News 6: Advances in Precision MedicineAdvances in precision medicine are transforming the way diseases are diagnosed and treated. With the use of genetic testing and personalized therapies, doctors can now tailor treatments to individual patients, increasing their chances of success and reducing side effects. This approach has already shown promising results in various types of cancer and is expected to revolutionize healthcare.## News 7: Artificial Intelligence in Drug DiscoveryArtificial intelligence is revolutionizing drug discovery. By analyzing vast amounts of data and predicting drug interactions, AI algorithms can significantly speed up the process of developing new medications. This technology has the potential to bring innovative treatments to patients faster and at a lower cost.## News 8: Biotech Startups Making WavesBiotech startups are making waves in the industry with their innovative technologies and therapies. These startups are challenging the status quo and bringing fresh ideas to the table. With their agility and outside-the-box thinking, they have the potential to disrupt the market and drive significant advancements in healthcare.## News 9: Regulatory Approvals for New TreatmentsRegulatory agencies are working diligently to expedite approvals for new treatments. Recognizing the urgent need for innovative therapies, these agencies are streamlining processes and prioritizing patient access to life-saving medications. This commitment to efficient regulation is crucial in addressing unmet medical needs.## News 10: Global Collaboration in Vaccine DistributionGlobal collaboration is key in ensuring equitable distribution of vaccines worldwide. Many countries and organizations have come together to support vaccine distribution efforts in low-income countries. By working together, we can ensure that no one is left behind in the fight against infectious diseases.That's all for today's episode of Pharma and Biotech daily. S

For many people, vaccines for flu, viruses and COVID-19 strains are extremely effective at warding off the diseases they're designed to protect against. But for some, including the elderly and people with chronic diseases, the results can be less effective.

Quite a day yesterday as Liz Cheney and Hillary Clinton surface - each screeching from their political ash heap about the dangers that await us if Jim Jordan becomes the next Speaker of the House and/or Donald Trump becomes the president. A new poll confirms the issues are solidly behind Republicans all the way. Biden is allegedly kicking the crap out of his dog at the White House. And the Nobel Prize has been awarded to two Penn scientists who are credited with developing the COVID shot. Dr. Robert Malone - credited with the science that laid the groundwork for their shot development explains what this award means, and then a very interesting discussion ensues about the trustworthiness of your own family doctor that you need to hear. -For more info visit the official website: https://chrisstigall.comInstagram: https://www.instagram.com/chrisstigallshow/Twitter: https://twitter.com/ChrisStigallFacebook: https://www.facebook.com/chris.stigall/Listen on Spotify: https://tinyurl.com/StigallPodListen on Apple Podcasts: https://bit.ly/StigallShowSee omnystudio.com/listener for privacy information.

You've probably seen Dr. Peter Hotez on the news before, being interviewed, sited, or – sometimes – skewered. He's made a name for himself in the fight against anti-science and was a constant presence as a primetime source during the COVID-19 pandemic. Dr. Hotez is the founding Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine where he is also the Co-director of the Texas Children's Center for Vaccine Development and Texas Children's Hospital Endowed Chair of Tropical Pediatrics. He is also University Professor at Baylor University. His latest book is "The Deadly Rise of Anti-Science: A Scientists Warning."He joins The Linecast to talk about his run-in with Elon Musk, Joe Rogan, and Robert F. Kennedy, Jr.; his work to fight anti-science rhetoric; and the what the future holds for us in navigating, what often seems like, a post-truth world. You can find Dr. Hotez on X. Hosted on Acast. See acast.com/privacy for more information.

Ali Velshi is joined by Bob King, Fmr. President of the UAW, Dr. Peter Hotez, Co-Director for Center for Vaccine Development at Texas Children's Hospital, Lisa Rubin, MSNBC Legal Analyst, Melissa Redmon, Fmr. Fulton County Deputy District Attorney, Rep. Debbie Dingell, (D) Michigan, Adm. James Stavridis, Fmr. Supreme Allied Commander at NATO, Michael Hirsh, Senior Correspondent, Foreign Policy, and Steve Benen, Producer of The Rachel Maddow Show.

From the frontlines of the fight against vaccine, and other scientific, misinformation, Peter Hotez, MD, PhD, founding dean of the National School of Tropical Medicine, codirector of the Texas Children's Center for Vaccine Development, and professor of pediatrics and molecular virology and microbiology at Baylor College of Medicine and the author of The Deadly Rise of Anti-Science: A Scientist's Warning (Johns Hopkins University Press, 2023), offers a framework for separating the politics from the science.

In this episode of the 5 Second Rule, hosts Kelly and Lerenza interview Dr. Peter Hotez, a vaccine scientist and autism parent, who shares his insights from the recent COVID-19 pandemic and provides strategies to better equip IPC programs for the future. His enlightened advice about anticipating and preparing for emerging infections, combined with his inspiring view of addressing vaccine skepticism, makes this episode a must-listen for anyone looking to protect their community from infectious diseases. Hosted by: Lerenza Howard, MHA, CIC, LSSGB and Kelly Holmes, MS, CIC About our Guest: Peter Hotez, MD, PhD, Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine Hotez is Dean of the National School of Tropical Medicine, Professor of Pediatrics, and Professor of Molecular Virology and Microbiology at Baylor College of Medicine. He is also the Director of the Texas Children's Center for Vaccine Development and Texas Children's Hospital Endowed Chair of Tropical Pediatrics. Additionally, Hotez is University Professor at Baylor University and a Fellow in Disease and Poverty at the James A Baker III Institute for Public Policy. Hotez was among the first to predict Zika's emergence in the U.S. and has served on infectious disease task forces for two consecutive Texas Governors. As an internationally recognized physician-scientist in tropical diseases and vaccine development, he is called upon frequently to testify before Congress. While at the Clinton Global Initiative, Hotez co-founded the Global Network for Neglected Tropical Diseases. In 2017, he was named by Fortune magazine as one of the 34 most influential people in healthcare; in 2018, he was appointed by the U.S. State Department to serve on the Board of Governors for the U.S. Israel Binational Science Foundation. Hotez received the Sackler Award in Sustained Leadership from Research!America. He was also the recipient of APIC's 2022 Distinguished Scientist Award.

Kathleen Neuzil, MD, MPH, is the Myron M. Levine MD, DTPH Professor in Vaccinology, professor of medicine and pediatrics, and is the director for the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. Mike Sacopulos speaks with Neuzil about her chapter in the book, Lessons Learned: Stories from Women Physician Leaders, her work for a non-profit, and her work in academic medicine. Throughout her career the power of mentorship, both as beneficiary and as benefactor, has been an inspiration to her. But what makes a good mentor? How do women find role models who balance a family and a successful career? How has the aftermath of the COVID-19 pandemic had an impact on women and young families advancing in their healthcare careers? Neuzil's leadership story is inspirational. She shares how small acts of kindness, via mentorship, can result in tremendous returns. Her clinical and policy talent, anchored on the bedrock of science, has benefited countless people around the globe. Learn more about the American Association for Physician Leadership at www.physicianleaders.org

Kathleen Neuzil, MD, MPH, is the Myron M. Levine MD, DTPH Professor in Vaccinology, professor of medicine and pediatrics, and is the director for the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. Mike Sacopulos speaks with Neuzil about her chapter in the book, Lessons Learned:  Stories from Women Physician Leaders, her work for a non-profit, and her work in academic medicine. Throughout her career the power of mentorship, both as beneficiary and as benefactor, has been an inspiration to her. But what makes a good mentor?  How do women find role models who balance a family and a successful career? How has the aftermath of the COVID-19 pandemic had an impact on women and young families advancing in their healthcare careers? Neuzil's leadership story is inspirational. She shares how small acts of kindness, via mentorship, can result in tremendous returns. Her clinical and policy talent, anchored on the bedrock of science, has benefited countless people around the globe. Learn more about the American Association for Physician Leadership at www.physicianleaders.org  

 Delve into a thought-provoking discussion surrounding the evolving landscape of COVID-19, vaccine developments, and the insights of David Dodd, Chairman and CEO of geoVax. The segment addresses the dynamics of mask-wearing, efficacy of masks, and the nuanced public perception. The conversation touches on the industry response to the recent upsurge in COVID-19 cases, the role of variants, and the impact on different population groups. Mark Cox engages with David Dodd to unpack geoVax's unique approach to vaccine development, highlighting its focus on compromised immune systems. Amid discussions of mRNA vaccines, Dodd clarifies the technology behind geoVax's next-generation vaccine and its potential benefits.  

Paul A. Offit, MD, is Director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children's Hospital of Philadelphia. He is the Maurice R. Hilleman Professor of Vaccinology at the Perelman School of Medicine at the University of Pennsylvania. Dr. Offit is an internationally recognized expert in the fields of virology and immunology, and was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention. He is a member of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee, and a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine and co-editor of the foremost vaccine text, Vaccines. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal. Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq®, recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. Read Dr. Offit's complete bio here: https://www.chop.edu/doctors/offit-paul-a _______________________________________________________ JOWMA Podcast | Ep. 1 How to Fool Yourself Less Often: Medical Decision Making for Regular People https://anchor.fm/jowma/episodes/Ep--1-How-to-Fool-Yourself-Less-Often-Medical-Decision-Making-for-Regular-People-eav2pu _______________________________________________________ Become a JOWMA Member! www.jowma.org  Follow us on Instagram! www.instagram.com/JOWMA_org  Follow us on Twitter! www.twitter.com/JOWMA_med  Follow us on Facebook! https://www.facebook.com/JOWMAorg/ Stay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

On this week's episode of The New Abnormal, Daniel Lippman, a reporter at Politico, tells us all about the ‘CEO of Anti Woke Inc.', who has his eyes on the presidency. Plus, Dr. Peter Hotez, co-director of the Texas Children's Hospital Center for Vaccine Development, talks to us about the triple threat of illness, anti-science, and anti-Semitism. Hosted on Acast. See acast.com/privacy for more information.

As 91-year-old Fox News mogul Rupert Murdoch carves his final deals before heading to the big newsroom in the sky, the world's focus is beginning to turn to his son and heir apparent, Lachlan. And according to The Daily Beast's Editor At Large Lachlan Cartwright, there's more to Murdoch junior than meets the eye. He explains on this week's episode of The New Abnormal: “It's important to note that Lachlan's politics are far more conservative than his father's.” Then, Dr. Peter Hotez, co-director of Texas Children's Hospital Center for Vaccine Development and Dean of the National School of Tropical Medicine at Baylor College of Medicine, tells podcast co-host Andy Levy his worries about the future of the House GOP and its “anti-science aggression” while “trying to create a witch hunt—not only against science, but against the scientists.” Hosted on Acast. See acast.com/privacy for more information.

The CDC is investigating a rise in severe cases of strep throat among kids in the U.S. Several children's hospitals across the country have reported an increase in strep cases since November, including in Colorado where two children died. Dr. Peter Hotez of the Texas Children's Hospital Center for Vaccine Development joined Geoff Bennett to discuss. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

There's GOP in-fighting among Trumpy Republicans when it comes to future House leadership positioning and Fox News host Tucker Carlson made it a whole lot worse. What is going on? New Abnormal podcast co-host Andy Levy and Daily Beast politics editor and guest host Matt Fuller try to figure it out and answer the questions they have about it, in the latest episode. Plus! Dr. Peter Hotez, co-director of Texas Children's Hospital Center for Vaccine Development, warns Andy about the holiday COVID wave that's coming and the scary twist that will make it unlike past waves. And Daily Beast politics reporter Will Sommer, also co-host of the podcast Fever Dreams about the shenanigans of the far right, joins to tell Andy all about the racist, sexist alt-right homophobe who raised $1 million for an alt-right superhero movie and promptly lost it in the most hilariously dumb way. Hosted on Acast. See acast.com/privacy for more information.

More than two years into the COVID-19 pandemic, there are still many questions that we sort of think we know the answers to, and many others we don't. We do know vaccine effectiveness wanes, and that vaccines need to be updated to keep pace with an evolving virus. We don't know if next-generation vaccines will be as effective against current variants as the original shots were against COVID Classic. We do know that the virus is substantially less deadly now that we've built up a big wall of immunity, but it still manages to infect most people, sometimes even multiple times a year. Is this a level of disruption we're just going to have to tolerate indefinitely? Would anyone really be satisfied with the existing level of COVID risk continuing in perpetuity? And is our healthcare equipped to deal with the ongoing and compounding effects of long COVID? Dr. Peter Hotez, professor of pediatrics and molecular biology at Baylor College of Medicine and co-director of Texas Children's Hospital Center for Vaccine Development, joins Brian to discuss the known knowns, known unknowns, and the unknown unknowns of COVID—and whether ongoing research can provide the answers we need.

[This episode is a re-release of Ep 27 Vaccines Part 2: Have you thanked your immune system lately?, originally published May 21, 2019]Were you stoked about the history and biology of vaccines we covered in part 1, but left with even more questions? Were you really hoping to hear us talk about anti-vaccine sentiment and address misconceptions about vaccines in detail? Did you want even more expert guest insight?! Well then do we have the episode for you! Today, we delve into the history of the “anti-vaccine movement” which, spoiler alert, is nothing new. With the help of Dr. Peter Hotez, Dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston and Co-director of the Texas Children's Hospital Center for Vaccine Development we address some of the most common concerns and questions that arise about vaccines, their safety, and their efficacy. And finally, we hear from Bill Nye The Science Guy about dealing with the challenges of science communication in the modern world when diseases spread as fast as fake news headlines. Y'all. This is the episode you've been waiting for. You can follow Dr. Peter Hotez on twitter @PeterHotez and check out his book “Vaccines Did Not Cause Rachel's Autism” And you can listen to “Science Rules!” the new podcast from Bill Nye the Science Guy, available now on stitcher https://www.stitcher.com/podcast/stitcher/science-rules-with-bill-nye or wherever you are listening to this podcast!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.